4//SEC Filing
Altimmune, Inc. 4
Accession 0000899243-17-012363
$ALTCIK 0001326190operating
Filed
May 7, 8:00 PM ET
Accepted
May 8, 8:37 PM ET
Size
14.2 KB
Accession
0000899243-17-012363
Insider Transaction Report
Form 4
Altimmune, Inc.NASDAQ:ALT
Schafer Klaus
Director
Transactions
- Award
Stock Option (option to buy)
2017-05-04+1,791→ 1,791 totalExercise: $0.08From: 2017-05-04Exp: 2022-12-31→ Common Stock, par value $0.0001 (1,791 underlying) - Award
Stock Option (option to buy)
2017-05-04+1,791→ 1,791 totalExercise: $0.08From: 2017-05-04Exp: 2022-07-04→ Common Stock, par value $0.0001 (1,791 underlying) - Award
Stock Option (option to buy)
2017-05-04+1,791→ 1,791 totalExercise: $0.59From: 2017-05-04Exp: 2023-12-31→ Common Stock, par value $0.0001 (1,791 underlying) - Award
Common Stock, par value $0.0001
2017-05-04+5,998→ 5,998 total - Award
Stock Option (option to buy)
2017-05-04+4,775→ 4,775 totalExercise: $0.08From: 2017-05-04Exp: 2022-07-04→ Common Stock, par value $0.0001 (4,775 underlying)
Footnotes (2)
- [F1]Acquired pursuant to the Agreement and Plan of Merger, dated as of January 18, 2017 (as amended on March 29, 2017, the "Merger Agreement"), pursuant to which a wholly-owned subsidiary of the Issuer merged with and into Altimmune, Inc. ("Altimmune"). Pursuant to the Merger Agreement, the then outstanding shares of Altimmune's capital stock was converted into the right to receive a number of shares of the Issuer's common stock, par value $0.0001 on a 0.749106:1 basis upon the closing of the merger.
- [F2]Pursuant to the terms of the Merger Agreement, the Issuer assumed all outstanding options to purchase shares of Altimmune capital stock on a 0.749106:1 basis upon closing of the merger.
Documents
Issuer
Altimmune, Inc.
CIK 0001326190
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0001326190
Filing Metadata
- Form type
- 4
- Filed
- May 7, 8:00 PM ET
- Accepted
- May 8, 8:37 PM ET
- Size
- 14.2 KB